Drug intelligence / Profile preview

AD-2281 + AD-2282

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

**AD-2281 + AD-2282** is an investigational combination therapy comprising two small molecule drugs, AD-2281 and AD-2282, developed by Addpharma for the treatment of primary hypercholesterolemia. The combination is currently being evaluated in a phase 3 randomized, double-blind, active-controlled clinical trial to determine efficacy and safety in reducing LDL-C (low-density lipoprotein cholesterol) in adults with primary hypercholesterolemia. Both drugs are administered orally, once daily, for 8 weeks. Detailed mechanisms of action for AD-2281 and AD-2282 have not been publicly disclosed, but the combination is specifically targeted at lipid lowering for patients with primary hypercholesterolemia[1][3][7].

Beyond the preview

Go deeper on AD-2281 + AD-2282.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-2281 + AD-2282.

Explore the full profile